Results 61 to 70 of about 5,322,139 (136)

Proteasome Inhibitors Stimulate Activator Protein-1 Pathway Via Reactive Oxygen Species Production

open access: yes, 2009
In this report we explored the effects of proteasome inhibitors (MG132, aLLN, lactacystin and MG262) on interleukin-8 (IL-8) induction. In HEK293 cells, proteasome inhibitors could concentration-dependently increase IL-8 promoter and activator protein-1 (
LIN, WAN-WAN, 林琬琬
core  

The α5-α6-α7-Pba3-Pba4 complex: a starting unit in proteasome core particle assembly

open access: yes
A complex composed of Pba3-Pba4 and subunits α5, α6, and α7 is identified as an early intermediate in proteasome core particle assembly in wild-type Saccharomyces cerevisiae cells.
Dohmen, R. Jürgen   +4 more
core   +1 more source

Pharmacology of Proteasome inhibitors

open access: yes, 2020
A review on the pharmacology of proteasome inhibitors. It focuses on its pharmacokinetics and its pharmacodynamics, mechanism of action and its effect on the therapy of various cancers especially in multiple myeloma and solid tumors.általános ...
Omalu, Chinedu Stephen
core  

Proteasome inhibitors as anti-cancer agents.

open access: yes, 2000
The ubiquitin (Ub)-proteasome pathway is the major nonlysosomal pathway of proteolysis in human cells and accounts for the degradation of most short-lived, misfolded or damaged proteins.
Murray, Rachael   +3 more
core   +1 more source

Modifications in endopeptidase and 20S proteasome expression and activities in cadmium treated tomato (Solanum lycopersicum L.) plants

open access: yes, 2008
International audienceThe effects of cadmium (Cd) on cellular proteolytic responses were investigated in the roots and leaves of tomato (Solanum lycopersicum L., var Ibiza) plants. Three-week-old plants were grown for 3 and 10 days in the presence of 0.3–
Gallusci, Philippe   +7 more
core   +1 more source

Lab-on-a-chip and integrated strategies in tumor immunotheraphy [PDF]

open access: yes, 2011
Background While conventional chemotherapy and radiation therapy have improved the survival of many cancer patients, there are still major disadvantages associated with these treatments such as high toxicity and drug-resistance.
Destro, Federica
core  

Home - About - Disclaimer - Privacy